



Discovery Fueled by Ultra-Sensitivity

## Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call

Feb 16, 2024

BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 16, 2024-- [Quanterix Corporation](#) (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud Toloue, the Company's President and Chief Executive Officer, and Vandana Sriram, the Company's Chief Financial Officer.

Quanterix will issue a press release regarding the fourth quarter 2023 earnings and full year 2023 financial results prior to the conference call. The press release will be posted on the Quanterix website at <https://www.quanterix.com/>.

[Click here](#) to pre-register for the conference call and obtain your dial-in number and passcode. You can also visit this [link](#) to listen to the call via live webcast. You may also access the live webcast by visiting the [News & Events](#) page within the Investors section of the Quanterix website at [www.quanterix.com](http://www.quanterix.com). The webcast will be available on the Company's website for one year following completion of the call.

### About Quanterix

From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa<sup>®</sup> technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,500 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at <https://www.quanterix.com> or follow us on [Twitter](#) and [LinkedIn](#).

### Forward-Looking Statements

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.*

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240216642212/en/): <https://www.businesswire.com/news/home/20240216642212/en/>

### Media:

PAN Communications

Maya Nimnicht

510-334-6273

[quanterix@pancomm.com](mailto:quanterix@pancomm.com)

### Investor Relations:

Amy Achorn

(978) 488-1854

[ir@quanterix.com](mailto:ir@quanterix.com)

Source: Quanterix Corporation